XGES.L vs. BTEK.L
XGES.L (Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C) and BTEK.L (iShares Nasdaq US Biotechnology UCITS ETF) are both Health & Biotech Equities funds - XGES.L tracks the MSCI World/Health Care NR USD while BTEK.L tracks the NASDAQ Biotechnology TR USD. Both are passively managed. Over the past 3 years, XGES.L returned 1.51%/yr vs 10.19%/yr for BTEK.L. Their correlation of 0.82 suggests significant overlap in exposure. Both charge a 0.35% expense ratio.
Performance
XGES.L vs. BTEK.L - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, XGES.L achieves a -0.81% return, which is significantly lower than BTEK.L's 4.86% return.
XGES.L
- 1D
- 4.22%
- 1M
- 6.75%
- YTD
- -0.81%
- 6M
- -4.42%
- 1Y
- 26.00%
- 3Y*
- 1.51%
- 5Y*
- —
- 10Y*
- —
BTEK.L
- 1D
- 3.56%
- 1M
- 2.25%
- YTD
- 4.86%
- 6M
- 2.70%
- 1Y
- 43.15%
- 3Y*
- 10.19%
- 5Y*
- 5.85%
- 10Y*
- —
XGES.L vs. BTEK.L - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
XGES.L Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C | -0.81% | 11.22% | -1.38% | -7.92% | -8.46% |
BTEK.L iShares Nasdaq US Biotechnology UCITS ETF | 4.86% | 23.81% | -0.32% | 0.33% | 3.83% |
Correlation
The correlation between XGES.L and BTEK.L is 0.85, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.85 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.84 |
Correlation (All Time) Calculated using the full available price history since Jul 21, 2022 | 0.82 |
The correlation between XGES.L and BTEK.L has been stable across timeframes, ranging from 0.82 to 0.85 - a consistent structural relationship.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
XGES.L vs. BTEK.L — Risk / Return Rank
XGES.L
BTEK.L
XGES.L vs. BTEK.L - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C (XGES.L) and iShares Nasdaq US Biotechnology UCITS ETF (BTEK.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| XGES.L | BTEK.L | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.79 | ||
| Sortino ratioReturn per unit of downside risk | -0.98 | ||
| Omega ratioGain probability vs. loss probability | 1.25 | 1.38 | -0.13 |
| Calmar ratioReturn relative to maximum drawdown | 1.69 | 6.23 | -4.54 |
| Martin ratioReturn relative to average drawdown | 4.09 | 17.55 | -13.46 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| XGES.L | BTEK.L | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.45 | 2.24 | -0.79 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | 0.29 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.12 | 0.31 | -0.43 |
Drawdowns
XGES.L vs. BTEK.L - Drawdown Comparison
The maximum XGES.L drawdown since its inception was -35.79%, which is greater than BTEK.L's maximum drawdown of -30.86%. Use the drawdown chart below to compare losses from any high point for XGES.L and BTEK.L.
Loading charts...
Drawdown Indicators
| XGES.L | BTEK.L | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -35.79% | -30.86% | -4.93% |
Max Drawdown (1Y)Largest decline over 1 year | -15.29% | -6.89% | -8.40% |
Max Drawdown (3Y)Largest decline over 3 years | -25.52% | -26.34% | +0.82% |
Max Drawdown (5Y)Largest decline over 5 years | — | -30.86% | — |
Current DrawdownCurrent decline from peak | -12.59% | -1.86% | -10.73% |
Average DrawdownAverage peak-to-trough decline | -17.98% | -10.04% | -7.94% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.34% | 2.45% | +3.89% |
Volatility
XGES.L vs. BTEK.L - Volatility Comparison
The current volatility for Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C (XGES.L) is 6.45%, while iShares Nasdaq US Biotechnology UCITS ETF (BTEK.L) has a volatility of 6.91%. This indicates that XGES.L experiences smaller price fluctuations and is considered to be less risky than BTEK.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| XGES.L | BTEK.L | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.45% | 6.91% | -0.46% |
Volatility (6M)Calculated over the trailing 6-month period | 13.62% | 14.67% | -1.05% |
Volatility (1Y)Calculated over the trailing 1-year period | 17.84% | 19.14% | -1.30% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 18.27% | 20.08% | -1.81% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 18.27% | 21.71% | -3.44% |
XGES.L vs. BTEK.L - Expense Ratio Comparison
Both XGES.L and BTEK.L have an expense ratio of 0.35%.
Dividends
XGES.L vs. BTEK.L - Dividend Comparison
Neither XGES.L nor BTEK.L has paid dividends to shareholders.
Frequently Asked Questions
XGES.L and BTEK.L have a correlation of 0.85, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Both ETFs have the same 0.35% expense ratio. The better choice depends on whether you care most about return, fees, risk, or income.
XGES.L and BTEK.L have the same expense ratio: 0.35% per year.
XGES.L tracks MSCI World/Health Care NR USD, while BTEK.L tracks NASDAQ Biotechnology TR USD. They also come from different issuers: DWS and iShares.
Find the right allocation for XGES.L and BTEK.L
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer